- as new digital platform to tackle sickle-cell disease launches
Empowering frontline healthcare professionals with locally relevant medicines and clinical guidance is critical to achieving the best patient outcomes, Chief Executive Officer of EMGuidance, Yaseen Khan, has said.
He added that it is frequently difficult to have timely access to the relevant data needed to guide critical clinical decisions.
“Many times, however, quick access to the right information to drive important clinical decisions is not at hand,” he said.
To this end, his outfit, in partnership with the Ministry of Health, Novartis – a global healthcare company, and the Sickle Cell Foundation of Ghana, is set to introduce a new digital platform known as EMGuidance, which would connect healthcare practitioners to the local healthcare ecosystem and the medical industry, bringing comprehensive, up-to-date and locally relevant clinical information to healthcare workers.
The new digital healthcare platform which will be launched later this month is also expected to be an instrumental step forward in supporting the initiative to improve outcomes for patients suffering from Sickle Cell Disease.
Globally it is estimated that 15 million babies will be born with sickle-cell disease over the next 30 years, with up to 90 percent of them in low-income countries likely to die before reaching five years of age. Early detection and treatment of the disease, however, can substantially reduce mortality.
“Taking complex clinical information from across a medical ecosystem, and creating simple but powerful digital support at the point of care is at the heart of what EMGuidance does, and is particularly relevant in the treatment of Sickle Cell Disease.
“With the support and leadership of local Ghanaian medical partners, we believe this effort will enhance clinical guideline adherence by practitioners, supporting improved rates of screening and diagnosis, greater dosage and treatment and accuracy, and ultimately reducing crisis events, and supporting improved quality of life for patients with this disease,” Mr. Yaseen Khan has stated in a press release announcing the platform.
EMGuidance will serve as an independent medical platform that will be instrumental in carrying content and clinical information that supports the Sickle Cell Disease project to these healthcare professionals. However, the platform will not be restricted to this project alone, it will also bring its full service offering to the market.
EMGuidance launched in South Africa six years ago, and has grown rapidly, with 55 percent of healthcare practitioners in the country now signed up as subscribers.
With over 10,000 daily users and over one million searches per month, it is a powerful day-to-day clinical decision-making support tool trusted by doctors, nurses, pharmacists, and multinational pharmaceutical companies alike. It is free to use for registered health professionals.
